Diamonds and Dogs


Bristol-Myers (BMY) trading up 3% as the deal to acquire Celgene is moving forward. Bristol today announced Celgene will sell the rights to their psoriasis drug, Otezla to Amgen for $13.4 billion. The FTC required the sale of Otezla as a condition of allowing the merger. Bristol-Myers Squibb will move forward with its merger with Celgene, which was originally expected to have closed by now but has been delayed. Bristol-Myers said it would increase their buy back $7 billion in shares, increasing a previously announced $5 billion buyback.

 Good news for Amgen, bad news for Alexion Pharmaceuticals (ALXN). Alexion Pharma is down 3% today after dropping 3% on Friday following speculation of a buyout offer over the weekend. The rumored acquirer was Amgen. Well Amgen did make a deal over the weekend, but it was not for Alexion Pharma.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.